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Abstract
Background: Charcot-Marie-Tooth type 1A disease (CMT1A) is a rare orphan inherited neuropathy caused by an
autosomal dominant duplication of a gene encoding for the structural myelin protein PMP22, which induces abnormal
Schwann cell differentiation and dysmyelination, eventually leading to axonal suffering then loss and muscle wasting.
We favour the idea that diseases can be more efficiently treated when targeting multiple disease-relevant pathways.
In CMT1A patients, we therefore tested the potential of PXT3003, a low-dose combination of three already approved
compounds (baclofen, naltrexone and sorbitol). Our study conceptually builds on preclinical experiments highlighting a
pleiotropic mechanism of action that includes downregulation of PMP22. The primary objective was to assess safety
and tolerability of PXT3003. The secondary objective aimed at an exploratory analysis of efficacy of PXT3003 in CMT1A,
to be used for designing next clinical development stages (Phase 2b/3).
Methods: 80 adult patients with mild-to-moderate CMT1A received in double-blind for 1 year Placebo or one of the
three increasing doses of PXT3003 tested, in four equal groups. Safety and tolerability were assessed with the incidence
of related adverse events. Efficacy was assessed using the Charcot-Marie-Tooth Neuropathy Score (CMTNS) and
the Overall Neuropathy Limitations Scale (ONLS) as main endpoints, as well as various clinical and electrophysiological
outcomes.
Results: This trial confirmed the safety and tolerability of PXT3003. The highest dose (HD) showed consistent evidence
of improvement beyond stabilization. CMTNS and ONLS, with a significant improvement of respectively of 8%
(0.4% - 16.2%) and 12.1% (2% - 23.2%) in the HD group versus the pool of all other groups, appear to be the most
sensitive clinical endpoints to treatment despite their quasi-stability over one year under Placebo. Patients who
did not deteriorate over one year were significantly more frequent in the HD group.
Conclusions: These results confirm that PXT3003 deserves further investigation in adults and could greatly benefit
CMT1A-diagnosed children, usually less affected than adults.
(Continued on next page)
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Trial registration: EudraCT Number: 2010-023097-40. ClinicalTrials.gov Identifier: NCT01401257. The Committee for
Orphan Medicinal Products issued in February 2014 a positive opinion on the application for orphan designation for
PXT3003 (EMA/OD/193/13).
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Background
Charcot-Marie-Tooth disease Type 1A (CMT1A) (OMIM:
118220 and Orphanet:ORPHA101081) is a rare disease
belonging to the group of inherited, progressive, chronic
sensory and motor peripheral neuropathies referred to as
Charcot-Marie-Tooth (CMT) disease or also as “Hereditary
Motor and Sensory Neuropathy” (HMSN). Presently incur-
able, CMT is the most common inherited disorder of the
vperipheral nervous system [1,2]. CMT1A accounts for 70
to 80% of CMT Type 1 patients and for 40 to 50% of all
CMT patients [3-5]. Thus, CMT1A accounts for 50% of
patients with CMT, with an estimated prevalence of 1 in
5,000 [1,2,6]. CMT1A is caused by an autosomal domin-
antly transmitted intrachromosomal 17p11.2 duplication
harbouring PMP22, a gene encoding a myelin protein
[7,8]. PMP22 1.5-fold overexpression induces abnormal
Schwann cell differentiation, homogeneous and diffuse
nerve conduction slowing, and dysmyelination, eventually
leading to axonal loss and muscle wasting. A typical
feature of CMT1A includes weakness of the foot and
lower leg muscles which may result in foot drop and a
high-stepped gait with frequent tripping or falls [3,4].
Foot deformities are also characteristic due to weakness
of the small muscles in the feet, as well as “inverted
champagne bottle” lower legs appearance due to the
loss of muscle bulk. Later in the disease, weakness and
muscle atrophy may occur in the hands, resulting in
difficulty with fine motor skills. The severity of symptoms
is quite variable in different patients and even among
family members suffering from the disease.
There is currently no approved treatment available for
CMT1A disease. In preclinical studies, ascorbic acid
(AA) was shown to promote myelination in vitro and to
decrease PMP22 expression [9-11], and its mechanism
of action in the murine peripheral nervous system has
recently started to emerge [12]. Following these findings,
six clinical trials assessing efficacy and tolerability of 1-
or 2-year AA treatment have been published [13-18],
but no beneficial clinical effects are reported in any of
these trials. Considering the debilitating nature of the
disease and the absence of specific therapy there remains
a pressing unmet medical need for an efficacious and
safe treatment for CMT1A.
We have favoured the idea that diseases can be more
efficiently treated by targeting multiple pathways [19].
PXT3003 combines three drugs currently approved for
other indications: (RS)-baclofen (a γ-aminobutyric acid
[GABA]-B receptor agonist, used to treat spasticity), nal-
trexone hydrochloride (an opioid receptor antagonist, used
to treat opiate and alcohol addiction) and D-sorbitol (a
natural metabolite playing a role in the polyol pathway
and prescribed for intestinal disorders). In preclinical
experiments, the combination moderately lowers PMP22
mRNA expression while it has been shown to improve
impaired myelination and performances in CMT1A
transgenic rats [20] (companion manuscript). Additional
mechanisms of action of PXT3003 may exist since the
known targets of its components are expressed not only
in Schwann cells but also in peripheral neurons [21,22].
Moreover, PXT3003 is able to stimulate some axonal
regeneration in acute nerve crush model assessed by
the amplitude of Compound Muscle Action Potential
(CMAP) (companion manuscript). As it is well known
that preclinical and clinical therapeutic efficacy poorly
correlate [23] and as individual drugs of PXT3003
combination have rather high safety profile, we decided
to rapidly test it in CMT1A patients before studying
thoroughly its precise mechanism of action in various
models. In this one-year double-blind, randomised,
placebo-controlled, dose-ranging Phase 2 study, we
explore the potential of PXT3003 for the treatment of
CMT1A as a proof of concept to decide on further
investigations. The primary objective of the study is to
assess the clinical and laboratory safety and tolerability
of 3 doses of PXT3003 administered orally for 12 months
to CMT1A patients. The evaluation of the efficacy of
PXT3003 is the secondary objective, yet of a particular
importance for future investigations on PXT3003.
Methods
Patients
Patients were recruited into this double-blind, randomised,
placebo-controlled Phase 2 study at six hospital sites in
France (Marseille, Lille, Limoges, Lyon, Nantes and Paris)
from December 2010 to October 2011; the study ended
in November 2012 (EudraCT Number: 2010-023097-40,
ClinicalTrials.gov Identifier: NCT01401257). Inclusion
criteria were: age (18–65 years), CMT1A diagnosis based
on clinical examination and confirmation by genotyping
(duplication in 17p11.2), weakness in at least foot dorsi-
flexion, and a Charcot Marie Tooth Neuropathy Score
(CMTNS)≤20, i.e. a mild to moderate disability. Key
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than CMT1A, the use of unauthorized concomitant
treatments (including but not limited to baclofen, nal-
trexone, sorbitol, ascorbic acid, opioids, levothyroxine,
and potentially neurotoxic drugs), history of significant
hematologic, kidney or liver disease, insulin-dependent
diabetes or porphyria. Women of childbearing age were
excluded if they were pregnant, breastfeeding, or not
using adequate contraception. The protocol was approved
by the local ethics committee and regulatory authority
(Agence Française de Securité Sanitaire des Produits de
Santé). The study was done in accordance with the
Declaration of Helsinki and Good Clinical Practice
(GCP), and all patients gave written informed consent
before participation.
Selection of doses
The doses tested in human were chosen based on
extrapolation [24] from effective doses tested in CMT1A
rats for an oral administration twice daily in accordance
with the available pharmacokinetic data of the three
individual compounds.
Randomisation, masking and blinding
After a screening visit, eligible patients were randomly
assigned in a 1:1:1:1 ratio to receive daily for one year
Placebo, Low dose (LD=0.6 mg baclofen, 0.07 mg naltrex-
one and 21 mg sorbitol), Intermediate dose (ID=1.2 mg
baclofen, 0.14 mg naltrexone and 42 mg sorbitol) or High
dose (HD=6 mg baclofen, 0.7 mg naltrexone and 210 mg
sorbitol) of PXT3003 (Additional file 1: Table S1). A block
randomisation scheme stratified by study centre was used
to ensure a balance of treatment groups within each
centre. Once the eligibility of the patient was confirmed
by the investigator, patients were assigned a randomisa-
tion number according to a randomisation process using
an interactive web randomisation system (IWRS). Study
assignments were numbered according to a material ran-
domisation list, separate from the subject randomisation
list. Each patient’s assigned medication was determined by
his/her randomisation number. Blinding was ensured and
both patients and investigators were unaware of the
treatment allocation.
Both PXT3003 and Placebo were provided in amber
glass bottles containing 100 mL of clear solution, with
the same appearance and taste. The three dosages above
contain a quantity of sorbitol small enough to be coun-
terbalanced by the acetate buffer and easily masked by
the banana flavouring, not allowing to differentiate
them (by sight or taste) from Placebo. Study drug was
taken orally, using an adaptable graduated plastic pipette
for medication dispensation, twice a day (morning and
evening) during 12 months.
Procedures
Potentially eligible subjects were evaluated at screening
visits that included history, confirmation of CMT1A
genotyping, physical examination including vital signs
measurement (blood pressure, heart rate and weight),
electrocardiogram (ECG), concomitant medications, re-
cording of CMTNS and Overall Neuropathy Limitations
Scale (ONLS), centralised laboratory examinations blood
samples including Aspartate Aminotransferase (AST), Ala-
nine Aminotransferase (ALT), gamma-GT, total, conjugated
and un-conjugated bilirubinaemia, alkaline phosphatase,
creatininaemia, complete blood count (CBC) and differ-
ential count, platelet count, sodium, potassium, chloride
and blood glucose. Blood pregnancy test was obtained
for women of childbearing age at screening and after 12
months of treatment. If subjects met eligibility criteria,
they were randomised and enrolled in the study. An
independent Data Monitoring Committee (DMC) was
established to review all safety data at specified intervals
throughout the study. All patient data related to the study
were recorded on an electronic case report form (eCRF).
Safety and tolerability
We monitored the safety of PXT3003 during the study up
to 30 days after the last day of study drug administration,
based on adverse events reports from patients and labora-
tory tests (biochemistry and haematology). All adverse
events, whether or not considered by the investigator to
be related to the study medication, were to be recorded in
the patient’s medical records and in the eCRF. Serious
adverse events were reported by the study investigators.
A last follow-up visit consisting of a clinical examination,
adverse events records, concomitant treatments and labora-
tory tests was done 30 days after the last day of treatment.
The primary endpoint is the Incidence of related Adverse
Events (including possibly and probably related AE) with
moderate or severe intensity.
Compliance was measured after 1, 3, 6, 9 and
12 months by returned empty bottle count and volume
measurement (full and opened bottles). In the present
study, mean (s.d.) duration of exposure overall was 11.69
(1.53) months and was similar among the four groups,
and mean (s.d.) compliance with study drug was 97.3
(9.41%). Patients with compliance below 80% were
considered as low compliant.
Pharmacokinetics
Blood samples for pharmacokinetic (PK) assessment of
baclofen were drawn at randomisation (at peak only,
90 minutes after the first dose intake), 1, 6 and 12 months
(at trough and peak, before and after 90 minutes of drug
i n t a k e )o ra tt h ee n do fs t u d yd r u ga d m i n i s t r a t i o ni n
the case of patient’s discontinuation. Plasma concentra-
tion of baclofen was measured using a validated high-
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spectrometry (LC-MS/MS) in a central laboratory. Baclofen
plasma concentration at trough and at peak allowed us to
check the compliance of the study drug and to show the
kinetic of the drug according to the 3 doses.
However, because of the very low doses of naltrexone,
for most of the patients the plasmatic concentration was
found below the lower limit of quantification (LLOQ) of
the validated method (30 pg/mL) even at peak. At
12 months, naltrexone could be dosed at peak for only 16
patients (11 patients in the HD group, 3 in the ID group
and 2 in the LD group), and at trough for only 2 patients
in the HD group, while baclofen concentration could test-
ify that the patient had correctly taken PXT3003. Sorbitol
was not dosed for technical reasons as it could not be
detected under the conditions of the sampling.
Electrophysiology
Nerve conduction studies were performed using standard
techniques at skin temperature of 32°C. They included
motor and sensory responses of median and ulnar nerves
of the non-dominant upper limb.
For motor parameters (amplitude of Compound Muscle
Action Potential (CMAP), Motor Conduction Velocity
(MCV) and Distal Motor Latency (DML)), the median
nerve was stimulated at the wrist and antecubital fossa,
and responses were recorded over the abductor pollicis
brevis. The ulnar nerve was stimulated at the wrist and
below the elbow, and responses were recorded over the
abductor digiti minimi.
For sensory parameters (amplitude of Sensory Nerve
Action Potential (SNAP) and Sensitive Conduction Vel-
ocity (SCV)), we used an antidromic method and ring
electrodes by stimulating the nerves at the wrist. For the
median nerve, the active electrode was placed at the
base of the second digit and the reference electrode
between the fourth and the fifth metacarpals of the sec-
ond digit. For the ulnar nerve, the active electrode was
placed at the base of the fifth digit and the reference
electrode between the fourth and the fifth metacarpals
of the fifth digit.
Efficacy
Two composite neurological scores were used to address
efficacy in this study. The Charcot-Marie-Tooth Neur-
opathy Score (CMTNS) was proposed and validated by
Shy et al. to provide a single and reliable measure of
impairment in CMT [25,26]. It is a 36-point scale based
on 9 items comprising 5 of impairment (sensory symp-
toms, pin sensibility, vibration, strength arms and legs),
2 of activity limitations (motor symptoms arms and legs)
and 2 of electrophysiology (amplitudes of ulnar CMAP
and SNAP). Higher scores indicate worsening function,
and the score categorises disability as mild (0–10),
moderate (11–20) and severe (21–36). The Charcot-
Marie-Tooth Examination Score (CMTES) is a sub-score
of the CMTNS comprising only the first 7 items, excluding
the 2 electrophysiological items CMAP and SNAP.
Although CMTNS is an accepted measure of CMT
severity, its sensitivity to change is still debated and it
was agreed that some CMTNS components are not
sensitive, mainly because of floor and ceiling effects [27].
For instance, if the patient had surgery (fixation of the
ankle), the ‘motor legs symptoms’ definitively scores 3,
and no further decrease can be scored. The usefulness of
the SNAP component is also limited as it is frequently
absent in CMT1A patients who then receive the maximum
s c o r eo nt h e i re n t r yv i s i ta n dt hus have a low sensitivity to
change. Komyathy et al. (2013) pointed out that sensory
and motor symptoms items are based on subjective opinion
from patients, concerning their leg and arm strength
and loss of sensation in their legs, and that pin sensibil-
ity, vibration and strength are based on a neurological
examination which depends on patient cooperation and
examiner consistency to obtain reproducible results [28].
Finally, some measurement of CMTNS, such as SNAP or
vibratory sensation, may decrease with age, so that scores
from patients could increase slightly as they get older,
independently of CMT. A second, modified version of the
scale (CMTNS2) was therefore proposed by Murphy et al.
(2011), at a time when the present study was ongoing,
to attempt to reduce floor and ceiling effects and to
standardise patient assessment [29]. Although CMTNS
sensitivity in detecting the effects of a therapeutic interven-
tion has not been demonstrated up to now, it is the only
CMT-specific outcome measure (although not specific to
CMT1A subtype), used as primary outcome in the clinical
trials for ascorbic acid [16-18], and therefore remains of
particular interest for inter-study comparisons.
The Overall Neuropathy Limitations Scale (ONLS) was
derived and improved from the ODSS by Graham and
Hughes (2006) to measure limitations in the everyday
activities of the upper limbs (rated on 5 points) and the
lower limbs (rated on 7 points) [30]. The total score goes
from 0 (= no disability) to 12 (= maximum disability).
Although the functioning of patients with peripheral
neuropathy may be influenced by other factors in addition
to their physical capacity, ONLS measures the perceived
ability of the patient to move and enjoy a normal life, and
thus is expected to be associated with quality of life. It was
initially validated in a pool of 100 patients with diverse
peripheral neuropathies (mainly of dysimmune origin
but including 9 CMT patients), and it showed significant
relationships with measures of impairment, disability and
quality of life, although it did not correlate significantly
with the SF-36 Role Limitation Physical Subscale in
patients with neuropathies other than Guillain-Barré
Syndrome (GBS) and Chronic Inflammatory Demyelinating
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core disability scale for CMT1A studies [26,27]. Its reliabil-
ity was further validated in studies of CMT patients [31]
and it was also used in ascorbic acid therapeutic trials on
CMT1A patients [16,17].
The importance of both scores to assess impairment
and disability in CMT1A led us to consider them a priori
as main efficacy outcomes.
All other individual efficacy outcome measurements
were considered as secondary endpoints and were treated
equally. They included:
i) Functional measures:
 6-Minute Walk Test (6MWT) [32] to assess gait
velocity by the distance walked during six minutes
(in metres).
 9-Hole Peg Test (9HPT) to assess finger dexterity
by the time required to put nine pegs in nine holes
(in seconds, non-dominant hand considered).
 Quantified Muscular Testing (QMT) [33] to assess
muscle strength by Ankle Dorsiflexion (in Newton
metres, mean of left and right side considered) and
Hand Grip (in kilogrammes, non-dominant hand
considered).
ii) Electrophysiological parameters:
 Amplitude of Compound Muscle Action Potential
(CMAP, in millivolt), Motor Conduction Velocity
(MCV, in metres per second) and Distal Motor
Latency (DML, in millisecond) measured from the
mean motor responses of the median and ulnar
nerves (non-dominant side considered).
 Amplitude of Sensory Nerve Action Potential (SNAP,
in microvolt) and Sensitive Conduction Velocity
(SCV, in metres per second) measured from the mean
sensory responses of the median and ulnar nerves
(non-dominant side considered). The nerve sensory
measures have to be interpreted with caution because
of a particularly high content of missing values in
SCVand of 0 values in SNAP, the latter reflecting
measures below the detection threshold.
Myelin state of non-degenerated axons is generally
assessed by MCV, DML and SCV while CMAP and
SNAP inform on the degree of axonal loss, but it
must be stressed that the variability attached to these
measures is high.
iii) Self-assessment-based measurements:
 Visual Analog Scales (VAS) for pain, fatigue and
global state were assessed by the patient;
 Clinical Global Impression (CGI) for global
improvement, illness severity and therapeutic effect
was assessed by the physician.
All efficacy outcomes were assessed at randomisation
and at 6 and 12 months.
Additional exploratory outcomes
A set of additional, exploratory secondary outcomes
were monitored during the study.
 Intra-epidermal axon density in cutaneous biopsy of
the lateral malleolus.
 mRNA expression of PMP22 in cutaneous biopsy of
the lateral malleolus.
 Plasma concentrations of a series of bio-chemical
biomarkers.
Their analysis and interpretation of the results are still
ongoing, and will be the subject of future publications.
Between-sites standardisation
To standardise the outcome measures, the sponsor sup-
plied the material required for the 6MWT in the hospital
ward, the required tool to perform the 9HPT and the
required tool (MicroFet2 Jamar) to perform QMT. A
technical document detailed the techniques and material
used for these evaluations. Before the study began, all
examiners attended training sessions; an additional
training session was implemented at the opening of
each study site; furthermore, an audit was conducted
during the study on each site toc o n f i r mt h a ti n s t r u c t i o n s
were correctly followed. Moreover, all analyses (pharmaco-
kinetic and clinical laboratory evaluations) were centralised
and performed in two central laboratories.
Statistical analysis
Analysis population
All the analyses were conducted on the Full Analysis Set
(all randomised patients, on an intent-to-treat basis).
Baseline analysis
Demographic and clinical patient characteristics were
presented for each group [34].
Safety and tolerability analysis
Safety and tolerability analyses were based on the re-
ported treatment-emergent, adverse events (TEAEs) and
other safety information (vital signs, electrocardiogram
and laboratory tests). The percentage of patients with
treatment-emergent adverse events after one year was
descriptively compared between groups and tested by a
Fisher’s Exact Test.
Efficacy analysis
The composite scores used in this study (CMTNS and
ONLS) were considered as the main efficacy outcomes.
The monotonicity of the dose-effect was tested through
a Spearman’s rank correlation between percentage of
improvement and doses (numerically coded as Placebo=0,
LD=1, ID=2, HD=3). Differences between treatment
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(ANCOVA) on log-transformed values by adjusting for
baseline values. Estimates (LS-means) were provided as
mean percentage change over baseline. This analysis was
performed independently on CMTNS and ONLS. The
significance of the treatment effect on both CMTNS and
ONLS was then assessed through the significance of
the O’Brien’s OLS test [35,36] considered as the most
powerful method for the statistical inference of multiple
outcomes. In the context of the assessment of a combin-
ation of old drugs restrained to very low doses, we
suspected that the low dose and middle dose are a priori
located below the inflexion point of the expected logistic
dose–response function. Consequently, the Minimum
Effective Dose search was performed by closed Step-Down
procedure for comparing ordered doses with a control on
Helmert contrasts (SD2H algorithm, the ith dose level
mean is compared to the average of all the lower dose level
means, including the zero dose level) [37,38]. Based on the
assumption of monotonicity of the doses on the main
endpoints, the detection of a Minimum Effective Dose
among groups and a linear correlation coefficient of at
least R =0.75 between baseline and final values, a Stan-
dardised Mean Difference (also known as Cohen’s d)o f
at least s.m.d. = 0.5 should be detected with a power of
at least 80% when the sample size reaches 20 patients
per group and at a one-tailed 5% significance level
[39,40]. The treatment-by-centre interaction was assessed
on CMTNS and ONLS and we concluded that there was
no interaction. The ANCOVA analysis was repeated for
the other efficacy outcomes (6MWT, 9HPT, Ankle Dorsi-
flexion, Grip, CMAP, MCV, DML, SNAP, SCV, VAS and
CGI). Finally, we considered the patients non-deteriorated
(including stabilization or improvement) after the 12-
month treatment. Deterioration was evaluated by the
percentage of change averaged over CMTNS and ONLS.
The proportions of non-deteriorated patients in each group
were compared using a logistic regression model [41].
General procedures
Statistical analyses were performed with R version 3.0.1
(http://cran.r-project.org). Data distribution and within-
group variation were preliminary assessed in order to
guide our methodological choices [39-41]. Missing data
imputation was performed by mixed model approach
considered as the most appropriate technique for intent
to treat longitudinal studies [42]. Statistical tests were
conducted at a 5% significance level.
Results
Only seven patients (8.7%) left the study before comple-
tion. Demographic features, clinical characteristics and
reasons for drop-out were comparable between the
groups (Table 1 and Figure 1). Pharmacokinetic analyses
assessed drug exposure and compliance (Additional file 2:
Table S2).
Safety and tolerability
Safety and tolerability of PXT3003 were good, confirming
results from our regulatory preclinical studies and the
anticipated absence of toxicity at the chosen low doses.
Intake of the treatment did not indicate any influence on
the results of vital signs (blood pressure, heart rate and
weight), electrocardiogram measurements and laboratory
tests (biochemistry and haematology). The percentage of
patients with treatment-emergent adverse events (TEAEs)
after one year was similar across treatment groups (47% in
Placebo, 23% in LD, 33% in ID, 31% in HD, P=0. 48 ).Mo st
of the related TEAEs were mild and benign (Table 2).
Efficacy
Efficacy data suggested an increasing dose-effect for
PXT3003, significant on ONLS, DML and SCV (Table 3
and Figure 2). For most of the efficacy outcomes, the best
improvement was observed in the HD group (CMTNS,
ONLS, 6MWT, 9HPT, Grip, MA, MCV and SCV). A
Step-Down search of the Minimum Effective Dose identi-
fied the High dose as the most promising dose (Additional
file 3: Table S3). The other dose groups (LD, ID) can there-
fore be assimilated to Placebo, and the pool of the Pla-
cebo, LD and ID groups constitute from now the pooled
control group termed PLI (Table 4 and Figure 3).
CMTNS (Figure 4a) improved in the HD group com-
pared to Placebo, and improved significantly when com-
pared to PLI (8% of improvement, P= 0.042). ONLS
(Figure 4b) improved significantly in the HD group com-
pared to both Placebo (14.4% improvement, P =0.043)
and PLI (12.1% improvement, P=0.024). The significance
of the treatment effect on CMTNS and ONLS, assessed
through the multiple endpoints O’Brien’sO L St e s t ,
confirmed the improvement of the HD group compared
to Placebo (P =0.036) and PLI (P =0.0049). Among the
functional measures (including 6MWT, 9HPT, Ankle
Dorsiflexion and Hand Grip), 6MWT and Hand Grip
showed a trend toward improvement in the HD group
compared to PLI despite evidence of some training
effect assessed from the Placebo group and PLI. The
global significance of the treatment effect on the four
functional measures taken together with O’Brien OLS
test also confirmed an improvement in the HD group
compared to PLI (P =0 . 0 51 ) .
Electrophysiological results suggested that myelin func-
tion might have been improved. DML was significantly
decreased in the HD group when compared to Placebo
(8%, P =0.038), and SCV was significantly increased in
HD when compared to Placebo (26.6%, P =3.70×10
−4)
and PLI (20.1%, P =0.03). MCV was increased in the
HD group when compared to Placebo without reaching
Attarian et al. Orphanet Journal of Rare Diseases  (2014) 9:199  Page 6 of 15Table 1 Characteristics at baseline (Full Analysis Set, n =80)
Placebo
(n=19)
PXT3003 LD
(n= 21)
PXT3003 ID
(n=21)
PXT3003 HD
(n=19)
Mild/Moderate 3 (16%)/16 (84%) 4 (19%)/17(81%) 5 (24%)/16 (76%) 3 (16%)/16 (84%)
Women/Men 11 (58%)/8 (42%) 14 (67%)/7 (33%) 13 (62%)/8 (38%) 10 (53%)/9 (47%)
Age (years) 43.2 (12.2) 47.9 (14.9) 44.3 (12.7) 44.6 (11.2)
Body Mass Index 25.0 (3.9) 24.5 (4.0) 23.5 (3.5) 23.6 (4.6)
Disease Duration (years) 7.1 (5.5) 10.2 (13.1) 6.6 (4.5) 8.9 (5.5)
CMTNS 14.3 (3.8) 14.2 (4.1) 13.0 (4.0) 13.8 (3.4)
ONLS 3.1 (1.1) 3.3 (1.0) 3.5 (0.9) 3.6 (0.8)
6MWT (m) 468.2 (99.9) 473.1 (70.9) 450.7 (71.1) 429.3 (83.7)
9HPT (s) 17.2 (2.5) 16.1 (3.9) 18.4 (4.7) 20.8 (7.8)
Ankle Dorsiflexion (Nm) 7.8 (6.6) 9.1 (5.0) 8.3 (5.6) 8.2 (6.1)
Grip (kg) 22.6 (10.7) 21.6 (6.1) 23.1 (9.2) 20.6 (10.4)
CMAP (milliV) 3.7 (2.0) 4.0 (1.8) 3.7 (2.1) 3.4 (2.3)
MCV (m/s) 21.5 (3.6) 22.7 (4.7) 20.8 (4.8) 20.5 (5.3)
DML (ms) 8.6 (2.2) 7.9 (2.1) 8.2 (1.8) 8.2 (1.9)
SNAP (microV) 2.6 (3.2) 2.3 (3.0) 2.6 (3.8) 2.2 (2.7)
SCV (m/s) 31.1 (14.8) 29.4 (8.2) 31.3 (9.4) 29.9 (7.7)
Data are count (%) or mean (s.d.). CMTNS = Charcot-Marie-Tooth Neuropathy Score; ONLS = Overall Neuropathy Limitations Scale; 6MWT= 6-Minute Walk
Test; 9HPT =9-Hole Peg Test; CMAP = Amplitudes of Compound Muscle Action Potentials; MCV = Motor Conduction Velocity; DML= Distal Motor Latency;
SNAP = Amplitudes of Sensory Nerve Action Potentials; SCV = Sensitive Conduction Velocity. Mild: CMTNS≤ 10; Moderate: 11 ≤CMTNS ≤ 20.
19 allocated to Placebo 
17 (89,5%) completed 12 month
treatment and 16 (84,2%)
completed 1 month follow-up.
2 discontinued interventions:
1 Consent withdrawal (6 months) 
1 Consent withdrawal (3 months)  
+ Low compliance
1 lost to follow-up:
1 Pregnancy (discovered at 12 months)
21 (100%) completed 12 month
treatment and 20 (95,2%)
completed 1 month follow-up.
2 protocol violations: 
1 Low compliance
1 Prohibited medication
1 lost tofollow-up 
19 (90,5%) completed 12 month
treatment and 1 monthfollow-up.
2 discontinuedi nterventions: 
1 AE worsening (9 months)
1 Low compliance (6 months) 
2 protocol violations:
1 Viol. incl. criteria (CMTNS=21)
1 Non compliance
16 (84,2%) completed 12 month
treatment and 1 month follow-up.
3 discontinued interventions: 
2 Consent withdrawals  
(3 months and 6 months resp.)
1 Consent withdrawal (3 months)  
+ prohibited medication
1 Protocol violation 
1 Prohibited medication 
21 allocatedto PXT 3003 LD  21 allocated to PXT3003 ID  19 allocatedto PXT 3003 HD 
80 randomized 
99 assessed for eligibility 
19 excluded 
based on eligibility criteria
19 analysed 
(intention-to-treat population)
21 analysed 
(intention-to-treat population)
21 analysed 
(intention-to-treat population)
19 analysed 
(intention-to-treat population)
Figure 1 Diagram of the study design. The number of CMT1A patients randomised to each group and reasons for withdrawal are indicated.
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observed (P=0.18). This set of observations is consistent
with the putative mechanisms of action of PXT3003 that
may impact myelination, as shown ex vivo and in vivo with
the CMT1A rat model. As expected, the rate of missing
values in SCV was rather high (55%), as well as the
proportion of 0 values in SNAP (39.8%).
The quality of life assessed by VAS and CGI mea-
surements did not change when compared to Placebo
(Additional file 4: Table S4). In CMT, such self-assessment-
based scores are known to be independent with respect
to disease severity, and their ability to reflect a thera-
peutic effect in this short term treatment cannot be
confirmed [43,44].
Patients non-deteriorating after one year under HD appear
less affected at baseline
The proportion of patients non-deteriorated after 12 months
was similar in the Placebo, LD and ID groups (around
48%), and significantly higher in the HD group (79%,
Relative Risk 1.66, P = 0.01, Table 5). Comparison of
baseline characteristics between non-deteriorated and
deteriorated patients treated with PXT3003 HD sug-
gested that non-deteriorated patients were less severely
affected by the disease (Additional file 5: Table S5a): the
baseline value for most outcomes appeared better in non-
deteriorated patients, significantly for MCV and DML
(P=0.0051 and 0.01 respectively). The same comparison
was performed in the Placebo group as a negative control
and showed no trend or significant differences (Additional
file 5: Table S5b).
Discussion
Designing a clinical trial for CMT1A is a true medical
challenge. This debilitating and heterogeneous rare
disease has no approved reference treatment and its
natural history has only recently begun to be systemat-
ically explored. The number of patients with confirmed
diagnosis remains small, the disease progresses slowly
and the relevance of efficacy outcomes remains an
active topic of discussion, making it difficult to organise
at this stage a study specifically powered for efficacy
[45]. In this light, we consider the effects of PXT3003
described here as preliminary indications of drug activity,
rather than definitive conclusions on drug efficacy.
Despite all these limitations, this study provides a set
of relevant observations on the clinical measures, and
gives estimates of the magnitude of improvement after
one year of treatment under the doses tested.
This study confirms the safety and tolerability of
PXT3003. The highest dose shows consistent evidence
of modest improvement after 12 months, not only with
the data considered here but also in a comparison with a
pool including 445 patients from published Ascorbic
Acid studies suggesting the superiority of PXT3003
versus ascorbic acid (Figure 5). This preliminary result
deserves further reporting in a proper and complete
meta-analysis based on state-of-the-art methods.
Table 2 Most Frequent Study, Medication-Related, Treatment-Emergent Adverse Events (Frequency> 2.0% of the total
patients) by MedDRA System Organ Class and Preferred Term (Full Analysis Set, n= 80)
PXT3003 Placebo Total
High dose Intermediate dose Low dose
(n= 19) (n=21) (n=21) (n=19) (n=80)
n (%) n (%) n (%) n (%) n (%)
Any adverse event 6 31.6 7 33.3 5 23.8 9 47.4 27 33.8
Gastrointestinal disorders 4 21.1 1 4.8 1 4.8 6 31.6 12 15.0
Nausea 2 10.5 1 4.8 0 0.0 3 15.8 6 7.5
Abdominal pain 2 10.5 0 0.0 0 0.0 1 5.3 3 3.8
Diarrhoea 1 5.3 0 0.0 0 0.0 1 5.3 2 2.5
Nervous system disorders 3 15.8 2 9.5 2 9.5 2 10.5 9 11.3
Dizziness 1 5.3 0 0.0 2 9.5 2 10.5 5 6.3
Headache 0 0.0 2 9.5 0 0.0 0 0.0 2 2.5
Somnolence 2 10.5 0 0.0 0 0.0 0 0.0 2 2.5
General disorders and administration site conditions 0 0.0 1 4.8 1 4.8 3 15.8 5 6.3
Fatigue 0 0.0 1 4.8 1 4.8 1 5.3 3 3.8
Musculoskeletal and connective tissue disorders 1 5.3 1 4.8 1 4.8 1 5.3 4 5.0
Muscle spasms 1 5.3 1 4.8 0 0.0 0 0.0 2 2.5
Renal and urinary disorders 1 5.3 0 0.0 0 0.0 1 5.3 2 2.5
MedDRA= Medical Dictionary for Regulatory Activities. Study medication relationship was assumed if the relationship to study medication was judgeda s‘possible’
or ‘not assessable’ by the investigator or if the judgement was missing.
Attarian et al. Orphanet Journal of Rare Diseases  (2014) 9:199  Page 8 of 15Table 3 Response to PXT3003 on efficacy outcomes in treatment groups, with comparisons of active doses versus Placebo (Full Analysis Set, n =80)
Mean % of improvement PXT3003 LD versus Placebo PXT3003 ID versus Placebo PXT3003 HD
versus Placebo
Dose-effect
Placebo
(n= 19)
PXT3003 LD
(n=21)
PXT3003 ID
(n=21)
PXT3003 HD
(n=19)
Estimate P-value Estimate P-value Estimate P-value Correlation P-value
CMTNS 2.6 (17.5) 0.5 (23.2) −3.1 (16.0) 7.7 (18.4) −2.6 (−11.9;7.6) 0.67 −3.1 (−11.0;5.4) 0.74 5.5 (−3.4;15.2) 0.16 0.54 0.30
ONLS −5.3 (19.3) −6.5 (18.5) 4.8 (24.2) 12.3 (28.4) −3.9 (−14.2;7.6) 0.72 6.9 (−3.8;18.8) 0.15 14.4 (0.55;30.2) 0.043* 0.28 0.006*
6MWT (m) 9.0 (8.3) 6.2 (8.3) 6.4 (9.4) 9.9 (6.9) −2.4 (−6.2;1.5) 0.85 −2.4 (−6.6;2.0) 0.82 0.7 (−3.2;4.7) 0.38 0.11 0.16
9HPT (s) 4.9 (11.4) −1.2 (11.7) 5.6 (9.9) 7.8 (12.1) −4.6 (−10.3;1.5) 0.89 −0.2 (−5.3;5.2) 0.52 0.3 (−5.7;6.6) 0.47 0.15 0.092
Ankle Dorsiflexion (Nm) 20.2 (88.4) −3.6 (43.0) 81.5 (369.6) 20.4 (64.1) −4.0 (−21.7;17.8) 0.63 11.4 (−15.4;46.8) 0.26 8.2 (−13.8;35.9) 0.28 0.11 0.16
Grip (kg) 9.9 (24.2) 1.3 (15.6) 4.7 (12.5) 11.7 (18.1) −7.1 (−15.6;2.1) 0.90 −3.6 (−11.8;5.4) 0.75 1.6 (−7.7;11.9) 0.39 0.12 0.15
CMAP (milliV) 34.4 (62.0) 1.4 (38.7) 22.9 (62.6) 64.2 (208.5) −25.1 (−44.8;1.5) 0.94 −9.2 (−27.3;13.5) 0.77 −5.1 (−27.1;23.6) 0.63 −0.001 0.50
MCV (m/s) 3.7 (8.5) 3.0 (11.5) 5.7 (12.3) 9.0 (17.6) −1.0 (−6.5;4.9) 0.61 0.5 (−4.8;6.2) 0.44 2.8 (−3.4;9.4) 0.23 0.11 0.18
DML (ms) 0.4 (8.8) 3.6 (21.7) 15.3 (35.8) 8.4 (21.7) 3.4 (−4.3;11.7) 0.24 13.8 (4.2;24.3) 0.009* 8.0 (0.59;16.0) 0.038* 0.21 0.035*
SNAP (microV) 12.4 (121.7) 11.5 (88.2) 23.3 (128.4) 5.2 (69.0) −1.2 (−42.9;71.0) 0.52 8.7 (−31.2;71.6) 0.38 13.9 (−24.1;71.0) 0.29 0.09 0.30
SCV (m/s) 3.4 (11.0) 5.3 (11.2) 29.5 (63.4) 30.5 (10.0) 1.5 (−5.8;9.4) 0.36 17.5 (−5.5;46.2) 0.11† 26.6 (15.5;38.8) 0.00037* 0.42 0.01*
Data are mean % (s.d.) of improvement for each treatment group. Differences between treatment groups were assessed by Analysis of Covariance (ANCOVA) on log-transformed values by adjusting for baseline
values. Estimates were provided as mean percentage change over baseline (90% CI). Dose-effect was tested through Spearman’s rank correlation. P-values are one-tailed. *P < 0.05; Boldface = best improvement
within dosages. CMTNS = Charcot-Marie-Tooth Neuropathy Score; ONLS = Overall Neuropathy Limitations Scale; 6MWT = 6-Minute Walk Test; 9HPT = 9-Hole Peg Test; CMAP = Amplitudes of Compound Muscle
Action Potentials; MCV = Motor Conduction Velocity; DML = Distal Motor Latency; SNAP = Amplitudes of Sensory Nerve Action Potentials; SCV = Sensitive Conduction Velocity.
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5The clinical composite scores CMTNS and ONLS,
considered by us a priori as the two main endpoints,
appeared to be the most responsive clinical outcomes
despite their quasi stability after one year under Placebo.
The improvement of the four functional measures
(6MWT, Ankle dorsiflexion, Hand Grip and 9HPT)
reached significance in the HD group compared to PLI
(P =0.051) in a multivariate analysis using O’Brien OLS
test.
The evolution of Placebo subjects in our study and in
previous CMT1A trials [13-18] underlines the fact that
CMT1A patients deteriorate rather slowly. Shy et al.
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Figure 2 Summary of the efficacy analysis, active doses versus Placebo. Least squares mean percentages of relative improvement after
12 months along with 90% CI in all efficacy outcomes after 12 months for LD, ID and HD groups versus Placebo (obtained from Table 3). These
estimates and CI were assessed by the ANCOVA efficacy analysis and sorted from highest to lowest value. A negative value of improvement
means that the outcome was deteriorated after 12 months. Sample sizes: Placebo (n=19), LD (n=21), ID (n=21), HD (n=19). The two main
efficacy outcomes, CMTNS and ONLS, are indicated with red bold characters. *P<0.05.
Table 4 Response to PXT3003 on efficacy outcomes in HD and in PLI, with comparisons of HD versus PLI (Full Analysis
Set, n =80)
Mean % of improvement PXT3003 HD versus PLI
PLI
(n=61)
PXT3003 HD
(n= 19)
Estimate P-value
CMTNS −0.1 (19.0) 7.7 (18.4) 8.0 (0.4;16.2) 0.042*
ONLS −2.2 (21.2) 12.3 (28.4) 12.1 (2.0;23.2) 0.024*
6MWT (m) 7.1 (8.6) 9.9 (6.9) 2.6 (−0.73;6.1) 0.099
9HPT (s) 3.1 (11.3) 7.8 (12.1) 1.2 (−3.4;6.0) 0.33
Ankle Dorsiflexion (Nm) 33.1 (223.2) 20.4 (64.1) 5.5 (−12.8;27.7) 0.32
Grip (kg) 5.1 (17.9) 11.7 (18.1) 6.0 (−1.2;13.7) 0.088
CMAP (milliV) 19.6 (56.5) 64.2 (208.5) 6.6 (−15.8;35.1) 0.33
MCV (m/s) 4.2 (10.9) 9.0 (17.6) 2.5 (−2.4;7.7) 0.21
DML (ms) 6.7 (25.6) 8.4 (21.7) 2.2 (−5.1;10.0) 0.31
SNAP (microV) 15.9 (110.2) 5.2 (69.0) 12.0 (−23.9;64.9) 0.31
SCV (m/s) 12.7 (38.0) 30.5 (10.0) 20.1 (2.4;40.8) 0.030*
Data are mean % (s.d.) of improvement for HD and for PLI after 12 months. Differences between treatment groups were assessed by Analysis of Covariance
(ANCOVA) on log-transformed values by adjusting for baseline values. Estimates were provided as mean percentage change over baseline (90% CI). P-values are
one-tailed. *P < 0.05; Boldface = best improvement within groups. CMTNS = Charcot-Marie-Tooth Neuropathy Score; ONLS = Overall Neuropathy Limitations
Scale; 6MWT = 6-Minute Walk Test; 9HPT = 9-Hole Peg Test; CMAP = Amplitudes of Compound Muscle Action Potentials; MCV = Motor Conduction Velocity;
DML = Distal Motor Latency; SNAP = Amplitudes of Sensory Nerve Action Potentials; SCV = Sensitive Conduction Velocity.
Attarian et al. Orphanet Journal of Rare Diseases  (2014) 9:199  Page 10 of 15(2008) reported a natural deterioration of 0.686 points
in CMTNS per year [46]. In this study we observed no
such deterioration in patients under Placebo. The fact
that patients under Placebo do not experience the
natural progression of the disease was corroborated by
previous clinical trials, and notably discussed by
Pareyson et al. [17] and Lewis et al. [18]. The main
conclusion is that natural history data of changes in
the CMTNS cannot be used instead of a Placebo group in
clinical trials. It has been suggested that an effective treat-
ment for this disease should bring an improvement rather
than the mere ability to slow the disease progression [18].
Actually, the most important improvement after one
year in CMTNS and ONLS is observed in the HD group,
while the changes observed under Placebo are negligible
for CMTNS and with slight deterioration for ONLS
(Figure 4 and Table 3). Nevertheless, the magnitude of
improvement under treatment is rather small in this
one-year trial and this does not permit us to draw defini-
tive conclusions on the potential of PXT3003.
This promising finding could be interpreted through
some mechanistic hypothetical considerations. From pre-
clinical experiments it seems that the drug combination
PXT3003, which hits potentially multiple targets, induces
restoration and/or maintenance of Schwann cells and
myelin in Pmp22 rat model, and is also able to facilitate
axon regeneration in a mouse nerve crush model (com-
panion manuscript).
This pleiotropic effect could therefore ameliorate
CMT1A patients through 3 different hypothetical mech-
anisms: i) axonal preservation which would delay or
stabilise disease progression; ii) functional improvement
of non-degenerated but dysfunctional suffering axons;
iii) axonal regeneration. If axon preservation was the
only mechanism, it would stabilise or delay disease pro-
gression, but because of the slow disease progression,
assessing this effect would require several years of clinical
observation. Alternatively, mechanisms ii and iii could
explain an actual clinical amelioration of patients, instead
of mere stabilisation, in a relatively short period of time.
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Figure 3 Summary of the efficacy analysis, HD versus PLI. Least
squares mean percentages of relative improvement after 12 months
with 90% CI in all efficacy outcomes after 12 months for HD versus
PLI (obtained from Table 4), assessed by the ANCOVA efficacy
analysis and sorted from highest to lowest value. Sample sizes: PLI
(n=61), HD (n=19). The two main efficacy outcomes, CMTNS and
ONLS, are indicated with red bold characters. *P<0.05.
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Figure 4 Response to PXT3003 on clinical scales (Full Analysis Set, n=80). Mean % (s.e.m.) of improvement from baseline per group at
12 months for CMTNS (a) and ONLS (b). Sample sizes: Placebo (n=19), LD (n= 21), ID (n= 21), HD (n= 19).
Attarian et al. Orphanet Journal of Rare Diseases  (2014) 9:199  Page 11 of 15The fact that electrophysiological measures of deteri-
oration that are considered to reflect the state of myelin
(see Methods) correlate with the clinical severity of the
disease is one of the arguments favouring the possibility
that a clinical amelioration could be linked to the functional
improvement of dysmyelinated but preserved axons. In one
of the first electrophysiological studies of 69 CMT1 patients
[47], it was shown that peroneal nerve conduction velocity
was significantly associated with neurologic disability score
(NDS). But no such correlation was found in a cohort
of 42 CMT1A patients, and it was concluded that only
nerve action potentials (CMAP and SNAP), which reflect
the degree of axonal loss, correlate with clinical severity.
Still another group [48] reported a significant correlation
between the clinical severity of the disease and the median
nerve conduction velocity in a cohort of 51 CMT1A
Table 5 Proportion of non-deteriorated patients (Full Analysis Set, n =80)
Placebo
(n=19)
PXT3003 LD
(n= 21)
PXT3003 ID
(n= 21)
PXT3003 HD
(n=19)
HD versus Placebo HD versus PLI
Non-deteriorated 10 (52%) 10 (48%) 9 (43%) 15 (79%) Relative Risk P-value Relative Risk P-value
1.5 (1.03;1.77) 0.047* 1.66 (1.24;1.93) 0.010*
Data are count (%) of non-deteriorated patients per group and Relative Risks (90% CI) for the HD group versus Placebo and versus PLI assessed with a logistic
regression model. P-values are one-tailed. *P < 0.05.
CMTNS
C
h
a
n
g
e
 
f
r
o
m
 
B
a
s
e
l
i
n
e
,
 
C
M
T
N
S
 
u
n
i
t
s
−
1
.
5
−
1
.
0
−
0
.
5
0
.
0
0
.
5
1
.
0
1
.
5
AA 1g 
 Micallef
AA 1.5g 
 Pareyson
AA 3g 
 Micallef
Pool AA 
 Micallef, Pareyson
Pool Placebo 
 Micallef, Pareyson, PXT3003
PXT3003 HD
n = 56
1g
n = 122
1.5g
n = 61
3g
n = 239
n = 197
n = 19
Placebo
AA
PXT3003 HD
P = 0.058 
P = 0.019 *
a ONLS
C
h
a
n
g
e
 
f
r
o
m
 
B
a
s
e
l
i
n
e
,
 
O
N
L
S
 
u
n
i
t
s
−
0
.
4
−
0
.
2
0
.
0
0
.
2
0
.
4
AA 1g 
 Micallef
AA 1.5g 
 Pareyson
AA 3g 
 Micallef
Pool AA 
 Micallef, Pareyson
Pool Placebo 
 Micallef, Pareyson, PXT3003
PXT3003 HD
n = 56
1g
n = 118
1.5g
n = 61
3g
n = 235
n = 190
n = 19
Placebo
AA
PXT3003 HD
P = 0.064 
P = 0.025 *
b
Figure 5 Pooled analysis. Mean change from baseline after 12 months (s.e.m.) of (a) CMTNS and (b) ONLS for single studies and pooled
Placebo and ascorbic acid (AA) groups obtained from our study in addition to the French (Micallef et al. [16]) and Italian/UK (Pareyson et al.
[17]) Phase 2 trials. For ONLS in Pareyson, values at 24 months were used, as values at 12 months were not available. Estimates of change at
12 months in previous trials were extracted from publications. *P<0.05, t-test.
Attarian et al. Orphanet Journal of Rare Diseases  (2014) 9:199  Page 12 of 15patients. In subsequent follow up of these patients, it was
found that higher disability after 5 years is significantly
associated with lower values of median nerve conduction
velocity at baseline [49]. At least some of these discrepan-
cies might be due to the differences and biases in patient
recruitment. In our sample of 80 mild to moderate
CMT1A patients (CMTNS ≤20), we also found that, at
baseline, nerve conduction velocities were correlated with
disease severity: correlations of MCV with CMTES and
ONLS were respectively of −0.32 (P= 0.0067) and −0.37
(P= 0.0014).
Such correlation between MCV and disease severity,
observed in three independent studies, should be confirmed
in other studies. It may indicate that an improvement of
myelin could, by itself, ameliorate CMT1A patient’sc l i n i c a l
state even if the degree of axonal loss remains unchanged.
Actually, such therapeutic potential of PXT3003 on myelin
is suggested by histological and electrophysiological out-
comes after treatment not only of the Pmp22 transgenic rat
(companion manuscript) but also by the results on
electrophysiological data observed in this trial.
The degree of such early therapeutic response, possibly
related to a myelin improvement, should correlate with
the proportion of dysfunctional but preserved axons. As
this proportion is likely to be higher in patients with
lower disease severity, this hypothesis fits with our obser-
vation that patients who have milder myelin impairment,
as suggested by MCV and DML measures at baseline,
seem to better respond to one-year treatment.
Moreover, PXT3003 was able to stimulate some axonal
regeneration in acute nerve crush model as assessed by
the amplitude of CMAP but the effect on this parameter in
CMT1A transgenic rats was limited when the treatment
was started after the onset of the disease (companion
manuscript). It must be emphasized that in the present
clinical trial, CMAP and SNAP amplitudes were measured
at the distal part of the arm, innervated by long axonal
fibres. However, a putative therapeutic axonal regeneration
w o u l db em o r el i k e l yt oo c c u ro ns h o r t e r ,i . e .m o r ep r o x -
imal, less affected fibres for which electrophysiological
measures could not be performed in the present study.
Still, such evidence based on electrophysiological parame-
ters data must be taken cautiously because of the wide
variability attached to these measures.
Despite its modest magnitude, the early amelioration
observed by us could nevertheless be highly meaningful
since it could announce a change of disease course by
axon protection through a therapeutic action on myelin.
Obviously, our data suggest that even higher doses
could be tested and might potentially generate greater
amelioration. Longer treatment duration might also per-
mit us to observe a larger improvement compared to
Placebo through the various putative mechanisms discussed
above.
Conclusions
Taken together, these results suggest that PXT3003
combination deserves further clinical investigation. This
might require more effort in assessing the specificity and
the sensitivity of several outcomes. When designing a
further trial in adults, it can be anticipated that efficacy
would increase when including milder patients treated
with higher dose and over a longer period. These results
also suggest that PXT3003 could potentially be even more
beneficial to children with a CMT1A genotype diagnosis,
less affected than adults since much of the progression in
CMT1A occurs during the first two decades of life [50].
In this regard, it would be tempting to test whether this
treatment would be able to improve nerve conduction vel-
ocity in clinically unaffected CMT1A children. This would
confirm a therapeutic action on myelin and would permit
us to envision a preventive treatment in children, taking
advantage of the quite safe profile of PXT3003 suggested
by the nature and the low dosing of its compounds.
Companion manuscript
Chumakov I, Milet A, Cholet N, Primas G, Boucard A,
Pereira Y, Graudens E, Mandel J, Laffaire J, Foucquier J,
Glibert F, Bertrand V, Nave KA, Sereda MW, Vial E, Guedj
M, Hajj R, Nabirotchkin S, Cohen D. Polytherapy with a
combination of three repurposed drugs (PXT3003) down-
regulates Pmp22 over-expression and improves myeli-
nation, axonal and functional parameters in models of
CMT1A neuropathy. Orphanet J Rare Dis 2014, 9:201.
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